Amgen beats estimates and raises guidance

4 August 2023
amgen_hq_large

US biotech major Amgen (Nasdaq: AMGN) has announced financial results for the second quarter of 2023.

Revenue rose by 5.9% to $6.99 billion, above the FactSet consensus of $6.66 billion, while net income climbed to $1.38 billion, or $2.57 a share, from $1.32 billion, or $2.45 a share, in the same period a year ago.

Excluding non-recurring items, adjusted earnings per share of $5 beat the FactSet consensus of $4.49.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology